Kidswell Bio Corporation
TTSE:4584152.00
JPY
-2.00
(-1.30%)
ISIN
JP3386460004
Return %
Stock
S&P 500
1Y
-41.76
14.20
3Y
16.03
81.12
5Y
-68.40
68.34
Capital Structure
JPY
•
in mil. unless spec.Working Capital
JPY
•
in mil. unless spec.Growth Rates
JPY
•
in mil. unless spec.Quarterly Revenue
JPY
•
in mil. unless spec.Quarterly Earnings Per Share
JPY
•
in mil. unless spec.Quarterly Dividends Per Share
JPY
•
in mil. unless spec.Company Description
- CEO
- Shinya Kurebayashi
- Full Time Employees
- 32
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- 3-8-3 Nihombashihoncho Tokyo Japan 103-0023
- IPO Date
- Nov 20, 2012
- Website
- kidswellbio.com
- Similar Companies
- Business
- Kidswell Bio Corporation specializes in the development, manufacturing, and commercialization of biosimilars and regenerative medicine products. Its main products include biosimilar pharmaceuticals with four biosimilar products already launched by partner pharmaceutical companies in Japan. The company focuses on regenerative medicine utilizing stem cells from human exfoliated deciduous teeth (SHED) and cardiac stem cells (CSC) targeting pediatric diseases, orphan diseases, and intractable diseases. Its new biopharmaceutical segment works on anti-RAMP2 antibodies for cancer and eye diseases and other novel antibodies. The company also advances regenerative medicine therapies using intracardiac stem cells for pediatric congenital heart diseases and dental pulp stem cells for cleft lip, palate, and intestinal ganglion cell deficiency diseases. Recent major changes include the spin-off of its cell therapy business into a wholly owned subsidiary, S-Quatre Corporation, in April 2024 to advance SHED-based therapies and facilitate fundraising and partnerships. The company entered a basic agreement and contract with Alfresa Holdings and others for joint development of biosimilars to establish Japan's first domestic biosimilar supply chain including new development, manufacturing, and stable supply. It also joined a non-binding term sheet with Alfresa Holdings, Mycenax Biotech, and Chiome Bioscience to explore a joint venture focused on GMP manufacturing for biopharmaceuticals in Japan. Kidswell Bio is preparing clinical trial applications for SHED-related treatments and consulting with regulatory authorities to advance its pipeline. It concentrates management resources on biosimilars and cell therapy while promoting collaborations in new biopharmaceutical development. Founded in 2000 and headquartered in Japan, Kidswell Bio operates primarily in the Japanese market with ongoing international collaborations. The company leverages strategic alliances and manufacturing partnerships to enhance its biosimilar portfolio and advance regenerative medicine solutions for complex diseases, maintaining a strong focus on innovation and domestic supply chain stability in biopharmaceuticals. This profile reflects Kidswell Bio Corporation's comprehensive biosimilar product commercialization, regenerative medicine R&D, recent strategic spin-off and partnership ventures, and its role in Japan's biopharmaceutical manufacturing landscape as of late 2025.